Payment overview · 2025
General Payments
$2,261.98
99 reported records · 28 companies
Healthcare provider profile · identity verified
Joseph Shaun Murphy, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CARROLLTON, TX · NPI 1871698316
Verified facts
What the public records show
CMS Open Payments records show Joseph Shaun Murphy, MD received $2,261.98 in general payments during 2025 across 99 reported records.
Amgen Inc. accounted for 10.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $244.91 | 10.8% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $243.40 | 10.8% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $240.21 | 10.6% | 19 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $173.73 | 7.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $152.15 | 6.7% | 9 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $145.86 | 6.5% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $113.20 | 5.0% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $109.89 | 4.9% | 5 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $97.29 | 4.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $90.85 | 4.0% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $89.48 | 4.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $67.45 | 3.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $52.45 | 2.3% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $51.71 | 2.3% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $51.34 | 2.3% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $48.74 | 2.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $43.93 | 1.9% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $38.63 | 1.7% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $33.78 | 1.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.40 | 1.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.34 | 1.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.41 | 0.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.71 | 0.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.97 | 0.8% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $17.62 | 0.8% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $17.19 | 0.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.65 | 0.7% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $13.69 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,261.98 | 99 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $221.69 | 8 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $173.73 | 2 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $173.73 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $170.12 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $170.04 | 13 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $168.93 | 4 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $145.86 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $109.89 | 5 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $97.29 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $89.48 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $72.00 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $70.17 | 6 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $63.39 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $52.45 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $51.71 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $51.34 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $48.74 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.09 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $46.98 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $46.98 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $46.98 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $44.88 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $43.93 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.87 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.94 | 4 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $38.63 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.97 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $33.78 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.19 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.91 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $3.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 285 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 240 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 188 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 177 | 56 |
| Losartan Potassium | Losartan Potassium | 177 | 48 |
| Trazodone Hcl | Trazodone Hcl | 150 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 148 | 49 |
| Gabapentin | Gabapentin | 118 | 32 |
| Ezetimibe | Ezetimibe | 96 | 31 |
| Carvedilol | Carvedilol | 91 | 26 |
| Furosemide | Furosemide | 87 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 23 |
| Celecoxib | Celecoxib | 78 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 78 | 28 |
| Montelukast Sodium | Montelukast Sodium | 74 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 23 |
| Meloxicam | Meloxicam | 72 | 24 |
| Metformin Hcl Er | Metformin Hcl | 69 | 26 |
| Allopurinol | Allopurinol | 68 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 24 |
| Omeprazole | Omeprazole | 64 | 22 |
| Ozempic | Semaglutide | 62 | 15 |
| Lisinopril | Lisinopril | 59 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 21 |
| Valsartan | Valsartan | 54 | 15 |
| Simvastatin | Simvastatin | 53 | 14 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 49 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 19 |
| Potassium Chloride | Potassium Chloride | 44 | 13 |
| Sertraline Hcl | Sertraline Hcl | 44 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 11 |
| Eliquis | Apixaban | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 12 |
| Synthroid | Levothyroxine Sodium | 39 | 11 |
| Irbesartan | Irbesartan | 38 | 12 |
| Spironolactone | Spironolactone | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 27 |
| Glipizide Er | Glipizide | 34 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 28 |
| Doxepin Hcl | Doxepin Hcl | 31 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 27 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | 11 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 11 |
| Valacyclovir | Valacyclovir Hcl | 24 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 22 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | 12 |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Metformin Hcl | Metformin Hcl | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | 12 |
| Prednisone | Prednisone | 16 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Qnasl | Beclomethasone Dipropionate | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,261.98 · 99 records | Amgen Inc. | ABRYSVO, APRETUDE, APTIMA, Auvelity, CAPVAXIVE, COMIRNATY, Cleerly Ischemia, Cleerly Labs, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FFRct, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FREESTYLE LIBRE 3, Fluad, Flucelvax, GARDASIL 9, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, REZDIFFRA, Rybelsus, SPRAVATO, TZIELD, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error